AR091402A1 - Profarmacos de acido fosforadimico - Google Patents
Profarmacos de acido fosforadimicoInfo
- Publication number
- AR091402A1 AR091402A1 ARP130102043A AR091402A1 AR 091402 A1 AR091402 A1 AR 091402A1 AR P130102043 A ARP130102043 A AR P130102043A AR 091402 A1 AR091402 A1 AR 091402A1
- Authority
- AR
- Argentina
- Prior art keywords
- propharmaces
- phosphoradimic
- acid
- channel function
- disorders
- Prior art date
Links
- 239000002253 acid Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 102000004310 Ion Channels Human genes 0.000 abstract 1
- 108090000862 Ion Channels Proteins 0.000 abstract 1
- 229910018830 PO3H Inorganic materials 0.000 abstract 1
- 102000004257 Potassium Channel Human genes 0.000 abstract 1
- 206010003119 arrhythmia Diseases 0.000 abstract 1
- 230000006793 arrhythmia Effects 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 108020001213 potassium channel Proteins 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6509—Six-membered rings
- C07F9/6512—Six-membered rings having the nitrogen atoms in positions 1 and 3
- C07F9/65128—Six-membered rings having the nitrogen atoms in positions 1 and 3 condensed with carbocyclic rings or carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Nutrition Science (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Un compuesto de la fórmula estructural (1) en donde R es H o -PO₃H, o una sal de aquel aceptable desde el punto de vista farmacéutico. Los compuestos son útiles como inhibidores de la función del canal de potasio y para el tratamiento y la prevención de arritmia, trastornos asociados IKᵘʳ y otros trastornos mediados por la función del canal iónico.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261657913P | 2012-06-11 | 2012-06-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR091402A1 true AR091402A1 (es) | 2015-02-04 |
Family
ID=48670111
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP130102043 AR091402A1 (es) | 2012-06-11 | 2013-06-10 | Profarmacos de acido fosforadimico |
Country Status (34)
| Country | Link |
|---|---|
| US (1) | US9238666B2 (es) |
| EP (1) | EP2858987B1 (es) |
| JP (1) | JP6234450B2 (es) |
| KR (1) | KR102092984B1 (es) |
| CN (1) | CN104350048B (es) |
| AR (1) | AR091402A1 (es) |
| AU (1) | AU2013274619B2 (es) |
| BR (1) | BR112014030629B1 (es) |
| CA (1) | CA2876359C (es) |
| CL (1) | CL2014003361A1 (es) |
| CO (1) | CO7160032A2 (es) |
| CY (1) | CY1120432T1 (es) |
| DK (1) | DK2858987T3 (es) |
| EA (1) | EA024692B1 (es) |
| ES (1) | ES2675314T3 (es) |
| HR (1) | HRP20180815T8 (es) |
| HU (1) | HUE039210T2 (es) |
| IL (1) | IL236074A (es) |
| LT (1) | LT2858987T (es) |
| MX (1) | MX356699B (es) |
| MY (1) | MY169219A (es) |
| NZ (1) | NZ703632A (es) |
| PE (1) | PE20150228A1 (es) |
| PH (1) | PH12014502747A1 (es) |
| PL (1) | PL2858987T3 (es) |
| PT (1) | PT2858987T (es) |
| RS (1) | RS57376B1 (es) |
| SG (1) | SG11201408076WA (es) |
| SI (1) | SI2858987T1 (es) |
| SM (1) | SMT201800369T1 (es) |
| TN (1) | TN2014000499A1 (es) |
| TW (1) | TWI571470B (es) |
| WO (1) | WO2013188254A1 (es) |
| ZA (1) | ZA201500161B (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2970295B1 (en) * | 2013-03-11 | 2016-12-28 | Bristol-Myers Squibb Company | Pyrrolopyridazines as potassium ion channel inhibitors |
| CN105026399B (zh) * | 2013-03-11 | 2017-06-23 | 百时美施贵宝公司 | 作为钾离子通道抑制剂的吡咯并三嗪类化合物 |
| US9050345B2 (en) * | 2013-03-11 | 2015-06-09 | Bristol-Myers Squibb Company | Pyrrolotriazines as potassium ion channel inhibitors |
| WO2017087594A1 (en) * | 2015-11-19 | 2017-05-26 | Biohaven Pharmaceutical Holding Company Ltd. | Amine prodrugs of pharmaceutical compounds |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5612359A (en) | 1994-08-26 | 1997-03-18 | Bristol-Myers Squibb Company | Substituted biphenyl isoxazole sulfonamides |
| GB9514380D0 (en) * | 1995-07-13 | 1995-09-13 | Knoll Ag | Therapeutic agents |
| TW536540B (en) | 1997-01-30 | 2003-06-11 | Bristol Myers Squibb Co | Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe |
| ID26984A (id) | 1998-07-06 | 2001-02-22 | Bristol Myers Squibb Co | Senyawa-senyawa sulfonamida sebagai antagonis reseptor angiotensin endotelin ganda |
| ES2215474B1 (es) | 2002-12-24 | 2005-12-16 | J. URIACH & CIA S.A. | Nuevos derivados de fosforamida. |
| AR049847A1 (es) | 2004-07-29 | 2006-09-06 | Merck & Co Inc | Inhibidores de los canales de potasio |
| CA2587664A1 (en) * | 2004-12-21 | 2006-06-29 | Devgen N.V. | Compounds with kv4 ion channel activity |
| PT2473487T (pt) | 2009-09-03 | 2017-01-04 | Bristol Myers Squibb Co | Quinazolinas como inibidores dos canais iónicos de potássio |
| AU2010289321A1 (en) | 2009-09-04 | 2012-04-05 | The Regents Of The University Of Michigan | Compositions and methods for treatment of leukemia |
| AR079814A1 (es) | 2009-12-31 | 2012-02-22 | Otsuka Pharma Co Ltd | Compuestos heterociclicos, composiciones farmaceuticas que los contienen y sus usos |
| JP5848761B2 (ja) * | 2010-06-24 | 2016-01-27 | アルカーメス ファーマ アイルランド リミテッド | Ｎｈ酸性化合物のプロドラッグ：エステル、カルボネート、カルバメートおよびホスホネートの誘導体 |
| US9050345B2 (en) * | 2013-03-11 | 2015-06-09 | Bristol-Myers Squibb Company | Pyrrolotriazines as potassium ion channel inhibitors |
| US9242966B2 (en) * | 2013-03-11 | 2016-01-26 | Bristol-Myers Squibb Company | Phthalazines as potassium ion channel inhibitors |
| JP2016516691A (ja) * | 2013-03-11 | 2016-06-09 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | カリウムイオンチャネル阻害剤としてのイソキノリン |
-
2013
- 2013-06-10 NZ NZ703632A patent/NZ703632A/en unknown
- 2013-06-10 PL PL13730444T patent/PL2858987T3/pl unknown
- 2013-06-10 PE PE2014002405A patent/PE20150228A1/es active IP Right Grant
- 2013-06-10 EA EA201492256A patent/EA024692B1/ru not_active IP Right Cessation
- 2013-06-10 CN CN201380030478.2A patent/CN104350048B/zh active Active
- 2013-06-10 SG SG11201408076WA patent/SG11201408076WA/en unknown
- 2013-06-10 AR ARP130102043 patent/AR091402A1/es not_active Application Discontinuation
- 2013-06-10 SI SI201331033T patent/SI2858987T1/en unknown
- 2013-06-10 HU HUE13730444A patent/HUE039210T2/hu unknown
- 2013-06-10 JP JP2015517321A patent/JP6234450B2/ja active Active
- 2013-06-10 AU AU2013274619A patent/AU2013274619B2/en active Active
- 2013-06-10 MY MYPI2014703715A patent/MY169219A/en unknown
- 2013-06-10 LT LTEP13730444.0T patent/LT2858987T/lt unknown
- 2013-06-10 PT PT137304440T patent/PT2858987T/pt unknown
- 2013-06-10 SM SM20180369T patent/SMT201800369T1/it unknown
- 2013-06-10 HR HRP20180815TT patent/HRP20180815T8/hr unknown
- 2013-06-10 TW TW102120593A patent/TWI571470B/zh active
- 2013-06-10 EP EP13730444.0A patent/EP2858987B1/en active Active
- 2013-06-10 RS RS20180738A patent/RS57376B1/sr unknown
- 2013-06-10 DK DK13730444.0T patent/DK2858987T3/en active
- 2013-06-10 KR KR1020157000330A patent/KR102092984B1/ko active Active
- 2013-06-10 ES ES13730444.0T patent/ES2675314T3/es active Active
- 2013-06-10 US US14/406,543 patent/US9238666B2/en active Active
- 2013-06-10 MX MX2014014525A patent/MX356699B/es active IP Right Grant
- 2013-06-10 WO PCT/US2013/044882 patent/WO2013188254A1/en active Application Filing
- 2013-06-10 BR BR112014030629-0A patent/BR112014030629B1/pt active IP Right Grant
- 2013-06-10 CA CA2876359A patent/CA2876359C/en active Active
-
2014
- 2014-11-28 TN TN2014000499A patent/TN2014000499A1/fr unknown
- 2014-12-04 IL IL236074A patent/IL236074A/en active IP Right Grant
- 2014-12-09 PH PH12014502747A patent/PH12014502747A1/en unknown
- 2014-12-10 CL CL2014003361A patent/CL2014003361A1/es unknown
-
2015
- 2015-01-08 CO CO15003999A patent/CO7160032A2/es unknown
- 2015-01-09 ZA ZA2015/00161A patent/ZA201500161B/en unknown
-
2018
- 2018-07-13 CY CY20181100733T patent/CY1120432T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12016502382A1 (en) | Substituted indazole compounds as irak4 inhibitors | |
| MX375970B (es) | Compuestos de triazolopirimidina y usos de los mismos. | |
| DOP2015000201A (es) | Compuestos de azabencimidazol como inhibidores de pde4 isoenzimas para el tratamiento del snc y otros trastornos | |
| CR20150078A (es) | Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn | |
| EA201691803A1 (ru) | Ингибиторы калликреина плазмы человека | |
| DOP2017000139A (es) | Nuevos compuestos y composiciones farmacéuticas de los mismos para el tratamiento de desórdenes inflamatorios y oesteoartritis | |
| CU20140072A7 (es) | Derivados de dihidro-oxazina y dihidro-pirido-oxazina | |
| UY35381A (es) | Pirrolotriazinas como inhibidores del canal del ion potasio | |
| CU20160192A7 (es) | Derivados de indano e indolina útiles como activadores de la guanilato ciclasa soluble | |
| MX362383B (es) | Moduladores de acido oxabiciclo[2.2.2] gpr120. | |
| CL2018002583A1 (es) | Derivado de morfolina | |
| UY37774A (es) | Compuestos 5-cianoindol sustituidos y usos de los mismos | |
| CU20150084A7 (es) | Derivados del ácido 4-((1,1) bisfenil -4-il)-3-(3-fosfonopropanamido)butanoico,activo como inhibidores de nep(endopeptidasa neutral) | |
| AR105821A1 (es) | COMPUESTOS ÚTILES PARA INHIBIR ROR-g-T | |
| EA201692300A1 (ru) | Производные карбоксамида | |
| MX390763B (es) | Compuestos de tetraciclina | |
| CR20150325A (es) | Compuestos trcíclicos para inhibir el canal cftr | |
| CO2019001644A2 (es) | Derivado de triazolopirazinona útil como un inhibidor de pde1 humana | |
| MX2016002718A (es) | Derivados de ceto-imidazopiridina como moduladores del receptor huerfano relacionado con receptor retinoide (porc). | |
| AR091402A1 (es) | Profarmacos de acido fosforadimico | |
| EA201650003A1 (ru) | Соединённые циклоалкилом дигетероциклические производные | |
| PE20141021A1 (es) | DERIVADOS DE TIENO [2,3-d] PIRIMIDINA COMO INHIBIDORES DEL CANAL DE POTASIO | |
| MX386902B (es) | Metodos para el tratamiento de trastornos cardiovasculares. | |
| AR094662A1 (es) | Compuesto útil para el tratamiento de enfermedades degenerativas e inflamatorias | |
| GT201500232A (es) | Compuestos de azabencimidazol como inhibidores de las isozimas pde4 para el tratamiento de cns y otros trastornos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |